Phase 3
Completed N=60
Interleukin-1 Blockade in Recently Decompensated Heart Failure
Source: ClinicalTrials.gov NCT01936909 ↗Enrolled (actual)
60
Serious AEs
32.7%
Results posted
Dec 2017
Primary outcomePrimary: Interval Changes in Peak Oxygen Consumption (VO2) — 14.05; 14.45; 13.3; 14.85 mL/kg/min — p=>0.20
◆ Published Evidence
Highly cited
235citations · ~26 / year
Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
Summary
The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.
Linked Publications
-
Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Interval Changes in Peak Oxygen Consumption (VO2) |
14.05; 14.45; 13.3; 14.85; 14.45; 12.65 | >0.20 |
| SECONDARY Quality of Life Improvement |
26.95; 23.45; 22.825; 37.575; 34.45; 28.7 | <0.01 sig |
| SECONDARY Death or Hospital Admission for Heart Failure |
4; 1; 3 | 0.12 |
Eligibility Criteria
Inclusion Criteria
All 6 criteria need to be met for enrollment of the patient in the study
- Primary diagnosis for hospitalization is decompensated heart failure established as the finding at admission of all 2 conditions listed below:
- dyspnea or respiratory distress or tachypnea at rest or with minimal exertion;
- evidence of elevated cardiac filling pressure or pulmonary congestion (at least one of the conditions must be met);
- pulmonary congestion/edema at physical exam OR chest X-Ray;
- plasma Brain Natriuretic Peptide (BNP) levels ≥200 pg/ml;
- invasive measurement of left ventricular end-diastolic pressure >18 mmHg or of pulmonary artery occluding pressure (wedge) >16 mmHg.
- The patient has a prior documentation of impaired left ventricular systolic function (ejection fraction 2 mg/L.
Exclusion Criteria Subjects will not be eligible if they meet any of the following 15 exclusion criteria.
- The primary diagnosis for admission is NOT decompensated heart failure, including diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or brady-arrhythmias.
- Concomitant clinically significant comorbidities that would interfere with the execution or interpretation of the study including but not limited to acute coronary syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders affecting respiration.
- Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT), coronary artery revascularization procedures, or heart valve surgeries.
- Previous or planned implantation of left ventricular assist devices or heart-transplant.
- Chronic use of intravenous inotropes.
- Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]).
- Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus).
- Active infection (of any type);
- Chronic/recurrent infectious disease (including Hepatitis B virus [HBV], Hepatitis C virus [HCV], and HIV/AIDS).
- Prior (within the past 10 years) or current malignancy.
- Any comorbidity limiting survival or ability to complete the study.
- End stage kidney disease requiring renal replacement therapy.
- Neutropenia (<2,000/mm3) or Thrombocytopenia (<50,000/mm3).
- Pregnancy.
- Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing obtained during the baseline testing.
Data sourced from ClinicalTrials.gov (NCT01936909) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.